EFFECT OF DENOSUMAB ON CLINICAL AND RADIOLOGICAL CHANGES IN RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS

Current  therapy for rheumatoid  arthritis (RA) should not only suppress inflammation, but should also prevent local and generalized bone mineral density (BMD)  loss. The drug of choice to treat secondary osteoporosis (OP) is denosumab, a monoclonal  antibody, which binds RANKL,  inhibiting the interaction  with its receptor,  which tends to reduce osteoclast activity and bone resorption.

Objective: to evaluate the effect of denosumab on BMD in the axial and peripheral skeleton of RA patients with OP. Subjects and methods. 52 postmenopausal women with RA and OP received subcutaneous denosumab 60 mg at baseline and after 6 months. BMD was measured at baseline and after 12 months,  by dual-energy X-ray absorptiometry at three sites: lumbar spine, femoral neck, and distal forearm.

Results. The patients’ mean age was 58.4±6.4  years; the mean RA duration  was 19.0±10.9 years. All the patients received anti-inflammatory therapy, including 30 (57.7%) patients who took glucocorticoids  (GC).  Preand

post-treatment BMD in the lumbar spine was 0.814±0.101 and 0.848±0.103 g/cm2  (р < 0.001), in the femoral neck – 0.629±0.089 and 0.641±0.090 g/cm2  (p = 0.02), in the distal forearm – 0.497±0.094 and 0.502±0.091 g/cm2 (р = 0.34) respectively. Regardless of the administration of GC,  stabilization or significant positive changes were noted in all the skeletal regions under study

Conclusion. Therapy with subcutaneous denosumab 60 mg twice a year at an injection interval of 6 months could significantly increase BMD in the lumbar spine and femoral neck and stabilize it in the distal forearm in RA patients with OP irrespective of the use of GC.

DOI: http://dx.doi.org/10.14412/1995-4484-2015-134-138

1. Насонов ЕЛ, Насонова ВА, редакторы. Ревматология. Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. С. 290. [Nasonov EL, Nasonova VA, editors. Revmatologiya. Natsional’noe rukovodstvo [Rheumatology. National Guide]. Moscow: GEOTAR-Media; 2008. P. 290.].

2. Goldring SR. Inflammation-induced bone loss in the rheumatic diseases. In: Primer on metabolic bone disease and disorders of mineral metabolism. Hoboken: John Wiley and Sons, Inc; 2009. Chapter 59.

3. Насонов ЕЛ, Скрипникова ИА, Насонова ВА. Проблема остеопороза в ревматологии. Москва: Стин; 1997. 429 с. [Nasonov EL, Skripnikova IA, Nasonova VA. Problema osteoporoza v revmatologii [The problem of osteoporosis in rheumatology]. Moscow: Stin; 1997. 429 p.].

4. Deodhar AA, Woolf AD. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol. 1996;35:309–22. doi: 10.1093/rheumatology/35.4.309

5. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292:490–5. doi: 10.1001/jama.292.4.490

6. Муравьев ЮВ, Дыдыкина ИС. Денситометрическая оценка минеральной плотности кости у больных ревматоидным артритом. Клиническая ревматология. 1995;(2):22–3. [Murav'ev YuV, Dydykina IS. Densitometric evaluation of bone mineral density in patients with rheumatoid arthritis. Klinicheskaya revmatologiya. 1995;(2):22–3 (In Russ.)].

7. Celiker R, Gokce-Kutsal Y, Cindas A, et al. Osteoporosis in rheumatoid arthritis: effect of disease activity. Clin Rheumatol. 1995;14:429–33. doi: 10.1007/BF02207677

8. Haugeberg G, Uhlig T, Flach JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis. Results from 394 patients in the Oslo country rheumatoid arthritis register. Arthritis Rheum. 2000;43:522–30. doi: 10.1002/1529-0131(200003)43:3<522::AIDANR7>3.0.CO;2-Y

9. Kroger H, Honkanen R, Saarikoski S, Alhave E. Decreased axial BMD in perimenopausal women with rheumatoid arthritis – a population-based study. Ann Rheum Dis. 1994;53:18–23. doi: 10.1136/ard.53.1.18

10. Cortet B, Guyot MH, Solau E, et al. Factors influencing bone loss in rheumatoid arthritis: a longitudinal study. Clin Exp Rheumatol. 2000;18:683–90.

11. Дыдыкина ИС, Максимов НА, Лесняк ОМ и др. Остеопороз: факторы риска, диагностика и фармакотерапия. Многоцентровое межрегиональное исследование в рамках программы «Северная звезда». Клиническая фармакология и терапия. 2007;16(2):84–8. [Dydykina IS, Maksimov NA, Lesnyak OM, et al. Osteoporosis: risk factors, diagnosis, and pharmacotherapy. Multicenter interregional study under the «North Star». Klinicheskaya farmakologiya i terapiya. 2007;16(2):84–8. (In Russ.)].

12. Дыдыкина ИС, Дыдыкина ПС, Насонов ЕЛ. Генноинженерные биологические препараты в терапии остеопороза у больных ревматоидным артритом. Остеопороз и остеопатии. 2013;(2):12–7. [Dydykina IS, Dydykina PS, Nasonov EL. Genetically engineered biological agents in the treatment of osteoporosis in patients with rheumatoid arthritis. Osteoporoz i osteopatii. 2013;(2):12–7. (In Russ.)].

13. Huusko TM, Korpela M, Karppi P, et al. Threefold increased risk of hip fracture with rheumatoid arthritis in Central Finland. Ann Rheum Dis. 2001;60:521–2. doi: 10.1136/ard.60.5.521

14. Orstavik RE, Haugeberg G, Uhlig T, et al. Self-reported non-vertebral fractures in rheumatoid arthritis and population based controls: incidence and relationship with bone mineral density and clinical variables. Ann Rheum Dis. 2004;63:177–82. doi: 10.1136/ard.2003.005850

15. Van Staa TP, Geusens P, Bijlsma JWJ, et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:3104–12. doi: 10.1002/art.22117

16. Подворотова ММ, Дыдыкина ИС, Таскина ЕА и др. Факторы риска переломов у больных ревматоидным артритом (предварительные результаты по материалам многоцентровой программы «Остеопороз при ревматоидном артрите: диагностика, факторы риска, переломы, лечение»). Научно-практическая ревматология. 2013;51(2):154–8. [Podvorotova MM, Dydykina IS, Taskina EA, et al. Risk factors for fractures in patients with rheumatoid arthritis (preliminary results of the multicenter program «Osteoporosis in rheumatoid arthritis: Diagnosis, risk factors, fractures, treatment»). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(2):154–8. (In Russ.)].

17. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008;29:155–192. doi: 10.1210/er.2007-0014

18. Лесняк ОМ, редактор; Российская ассоциация по остеопорозу. Клинические рекомендации по профилактике и ведению больных с остеопорозом. Ярославль: Литера; 2012.

19. с. [Lesnyak OM, editor; Russian Association of Osteoporosis. Klinicheskie rekomendatsii po profilaktike i vedeniyu bol'nykh s osteoporozom [Clinical practice guidelines for the prevention and management of patients with osteoporosis]. Yaroslavl': Litera; 2012. 24 p.].

20. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis. A 12-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;58(5): 1299–309. doi: 10.1002/art.23417

21. Dore RK, Cohen SB, Lane NE, et al. Effects of denosumab on bone mineral density and bone turnover in patients with RA receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis. 2010;69:872–5. doi: 10.1136/ard.2009.112920